From non-A, non-B hepatitis to hepatitis C virus cure  by Pawlotsky, Jean-Michel et al.
ReviewFrom non-A, non-B hepatitis to hepatitis C virus cure
Jean-Michel Pawlotsky1,2,⇑, Jordan J. Feld3, Stefan Zeuzem4, Jay H. Hoofnagle5
1National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France;
2INSERM U955, Créteil, France; 3Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Toronto,
Ontario, Canada; 4Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany; 5Liver Disease
Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health, Bethesda, MD, United StatesSummary
The hepatitis C virus (HCV) was discovered in the late 1980s.
Interferon (IFN)-a was proposed as an antiviral treatment for
chronic hepatitis C at about the same time. Successive
improvements in IFN-a-based therapy (dose ﬁnding, pegyla-
tion, addition of ribavirin) increased the rates of sustained viro-
logic response, i.e. the rates of curing HCV infection. These
rates were further improved by adding the ﬁrst available
direct-acting antiviral (DAA) drugs to the combination of pegy-
lated IFN-a and ribavirin. An IFN-free era ﬁnally started in
2014, yielding rates of sustained virologic response over 90%
in patients treated for 8 to 24 weeks with all-oral regimens.
Major challenges however remain in implementation of these
new treatment strategies, not only in low- to middle-income
countries, but also in high-income countries where the price
of these therapies is still prohibitive. Elimination of HCV infec-
tion through treatment in certain areas is possible but raises
major public health issues.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Twenty-ﬁve years after the discovery of the hepatitis C virus
(HCV), new orally administered antiviral drug combinations yield-
ing infection cure rates over 90% were approved in 2014–2015 in
Europe, the US and other regions of the world. Some called it a
‘‘revolution’’. A revolution is deﬁned by ‘‘a sudden, complete or
marked change in something’’. This deﬁnition does not apply to
what happened to the ﬁeld of HCV therapy. Instead, a slow, pro-
gressive, successful succession of discoveries in which academicJournal of Hepatology 20
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involved, led to the current situation (Fig. 1). It is the story of this
adventure, from discovery to cure, that we are telling here.To begin at the beginning
The era of discovery
In the 1960s and early 1970s, viral hepatitis was considered to
represent two clinically and epidemiologically distinct diseases:
infectious and serum hepatitis [1]. Infectious hepatitis, or hepati-
tis A, was marked by a short incubation period (1–3 weeks),
fecal-oral transmission, a high degree of contagiousness and an
acute self-limited illness that could be protracted and severe
(and even fatal) but did not result in chronic hepatitis or cirrhosis.
Serum hepatitis, or hepatitis B, in contrast was marked by a
longer incubation period (1–3 months), parenteral or sexual
transmission, a low degree of contagiousness, and an acute ill-
ness, that was usually self-limited but could be severe or fatal
and could also result in chronic infection, chronic hepatitis and
even cirrhosis. This duality was supported by human transmis-
sion studies [1] and by the discovery that the Australia antigen
was a part and parcel of the hepatitis B virus (HBV) [2–4], consid-
ered at the time to be the sole cause of serum hepatitis.
Development of sensitive tests for Australia antigen, later named
the hepatitis B surface antigen (HBsAg), provided means of diag-
nosis and screening that could be applied to blood donations and
prevention of post-transfusion hepatitis [5]. Application of donor
screening for HBsAg, however, led to a decrease in
post-transfusion hepatitis of only 25–50% [6]. The residual cases
were considered to be due to hepatitis A or to hepatitis B that was
not detected by the then-available serologic assays.
The discovery of the hepatitis A virus (HAV) was another land-
mark advance in hepatitis research and paved the way for devel-
opment of serological assays for diagnosis and epidemiologic
studies and ultimately for an HAV vaccine [7]. This discovery also
showed that hepatitis A was not a cause of post-transfusion hep-
atitis; indeed, virtually none of the non-B cases of hepatitis from
blood products could be linked to HAV [8]. The third form of viral
hepatitis was appropriately termed ‘‘non-A, non-B’’ (NANB)
hepatitis.15 vol. 62 j S87–S99
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Fig. 1. Progress in therapy of chronic hepatitis C genotype 1 as shown by SVR
rates with different antiviral regimens. PI, ﬁrst-wave, ﬁrst-generation protease
inhibitor (telaprevir or boceprevir); NA, nucleotide analogue (sofosbuvir).
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Fig. 2. Clinical, biochemical, histologic and virologic course of one of the
patients of a pilot study of IFN-a2b for chronic non-A, non-B hepatitis [12].
Serum ALT levels were consistently higher than 8 times the upper limit of normal
for a year before treatment and became normal within 1 month of starting IFN-a
(5 MU daily), but rose to pretreatment values within a few weeks of stopping.
Restarting IFN-a led to normalization of ALT levels again and they remained
normal for the subsequent year of treatment (using gradually lower doses of IFN)
and remained normal during long-term follow-up. A liver biopsy taken before
treatment showed marked activity (histology activity index 10) and mild ﬁbrosis
(Ishak ﬁbrosis score 1). At the end of treatment, the histology activity index score
had decreased to 3 and ﬁbrosis was no longer present. A repeat liver biopsy
10 years later showed similar minimal inﬂammation. Application of HCV RNA
testing by polymerase chain reaction on stored samples showed that therapy was
accompanied by loss of HCV RNA which remained undetectable in long-term
follow-up and was not detectable in the liver tissue taken 10 years later.
ReviewThe era of ‘‘non-A, non-B’’ hepatitis
Proof that there was another form of serum hepatitis was fol-
lowed by major efforts to discover its agent. The search would
continue for 15 years and employ all the methods that were suc-
cessful in discovery and characterization of hepatitis A and B
including immunodiffusion, complement ﬁxation, ﬂuorescence
microscopy, radio- and enzyme linked-immunoassay, electron
microscopy, transmission electron microscopy, immune electron
microscopy, cell and tissue culture, molecular biology and animal
transmission studies. Ultimately, the last two methods would
provide the basis for the discovery of the HCV, but until that time,
frustration ran high. Even without an identiﬁable agent, the clin-
ical and epidemiological characteristics of NANB hepatitis were
fairly well deﬁned [9].
The disease was due to a transmissible agent, probably a virus,
40–60 nm in size, enveloped, sensitive to heat and chloroform
inactivation. The disease was transmitted by blood and injection
drug use but rarely by sexual or maternal-infant exposure. Acute
infection tended to be mild and asymptomatic but could also
cause jaundice and severe hepatitis. Importantly, acute NANB
hepatitis frequently led to persistent infection and chronic
hepatitis, and could lead to cirrhosis and hepatocellular carcino-
ma. Later studies would show that acute HCV infection led to
persistent infection in at least 75% of cases and HCV was the most
common cause of chronic hepatitis, cirrhosis and hepatocellular
carcinoma in much of the Western world.
At the same time that the clinical features and outcomes of
NANB hepatitis were being described, advances were being made
in the therapy of hepatitis B, using interferon (IFN)-a as well as
antiviral agents that were effective in other viral infections.
These successes led to pilot studies of therapy for NANB hepatitis.
In small studies, corticosteroids were found to be ineffective,
indeed probably harmful [10]. Acyclovir was similarly ineffective,
even when given in high doses, intravenously [11]. IFN-a was an
obvious agent to try. In cell culture, IFN-a had demonstrable
antiviral activity against virtually all viral agents, both RNA and
DNA. Furthermore, recombinant forms of IFN-a had recently
been developed and the safety, tolerability, side effect proﬁle
and dosing requirements of the cytokine had been fairly well
deﬁned in studies of hepatitis B and D.
Accordingly, in early 1984, a pilot study of IFN-awas initiated
in 10 patients with well deﬁned chronic NANB hepatitis at the
Clinical Center of the National Institutes of Health (NIH) [12].
All 10 patients had risk factors for NANB hepatitis (bloodS88 Journal of Hepatology 201transfusion or injection drug use) and all had persistent and
stable, moderate-to-severe elevations in serum aminotransferase
levels and liver histology characteristic of chronic viral hepatitis.
The protocol called for use of the regimen found effective in
hepatitis B: 5 million units (MU) of IFN-a2b subcutaneously once
daily for 16 weeks.
The results were immediate and dramatic. Serum aminotrans-
ferase levels fell rapidly on IFN therapy and were often normal
within a month of starting treatment. This rapid change was
all-the-more convincing of an effect because the 10 patients
had previously been followed for 1–10 years and most had never
had a normal serum alanine aminotransferase (ALT) value. The
clinical, biochemical and ultimate virologic course of Patient 3
from that study is shown in Fig. 2. Within a month of starting
therapy, serum ALT levels were normal and they remained nor-
mal for the 16 weeks of the initial course. Within a month of
stopping treatment, ALT levels rose to baseline values. The
improvement in ALT levels recurred when IFN-a was restarted
and remained normal for a year of treatment despite a gradual
decrease in dose to 1 MU daily. Importantly, on stopping therapy
after a full year of treatment, serum ALT levels remained normal.
This pattern of rapid response to treatment, normalization of ALT
levels during a subsequent 12 months of therapy and lack of
relapse when IFN-awas stopped was seen in 5 of the 10 patients.
Three other patients developed normal or near-normal serum
ALT levels on therapy, but relapsed upon stopping. Two others
had only minimal decrease in ALT levels and little evidence of
improvement during long-term follow-up. Another striking fea-
ture found in these 10 subjects was that IFN-a was poorly toler-
ated in hepatitis C, and most patients required dose reduction.
These ﬁndings were reported in 1986 [12], several years
before the discovery of the HCV [13] and availability of sensitive
assays for HCV RNA in serum. When those tests were developed,
however, testing of stored serum samples showed that the
improvements in ALT levels were associated with decrease in
HCV RNA levels and that long-term remissions were5 vol. 62 j S87–S99
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accompanied by long-term clearance of detectable HCV RNA [14].
Subject 3 shown in Fig. 2 was the ﬁrst patient cured of hepatitis C
by antiviral therapy. In long-term follow-up of more than a quar-
ter of a century, he has remained free of evidence of HCV infec-
tion and liver injury with liver biopsy showing resolution of
disease activity and no detectable HCV RNA. The other four sub-
jects with a sustained biochemical response also had a sustained
virologic response (SVR) and were alive and without evidence of
liver injury 15–20 years later. In contrast, the ﬁve patients who
did not respond continued to have evidence of chronic hepatitis
and HCV RNA in serum; three developed hepatocellular carcino-
ma and all but one have died.
This pilot study of IFN-a in NANB hepatitis led to the initiation
of two randomized controlled trials. Both trials used a 24-week
course of treatment: a study from the NIH used 2 MU thrice
weekly with a placebo control [15], whereas a multicenter US tri-
al used either 1 or 3 MU thrice weekly with a non-treated control
[16]. Both studies showed that IFN-a treatment led to improve-
ments in serum ALT levels and liver histology, which was more
frequent in the 2 MU (48%) and 3 MU (46%) than the 1 MU
(28%) or control (0% and 8%) groups. Importantly, however, the
endpoint for efﬁcacy was measured at the end of treatment,
while still on IFN. Based upon these studies and the demonstra-
tion that HCV RNA was eradicated in some patients, IFN-a2b
was approved for use in chronic hepatitis C by the US Food and
Drug Administration in 1991.
The early era of hepatitis C and its treatment with IFN-a
The initial enthusiasm for IFN-a therapy was soon dampened by
experience in a broader spectrum of patients, by further
follow-up of treated patients, and the application of sensitive
virologic markers to treated patients. In 1997, an NIH
Consensus Development Conference concluded that treatment
of chronic hepatitis C with IFN-a was appropriate for patients
with raised serum aminotransferase levels, HCV RNA in serum
and liver histology showing ﬁbrosis or marked disease activity
[17]. The shortcomings of IFN therapy were the frequent side
effects and the relatively low rate of sustained responses.
Indeed, in subsequent large multicenter trials, the SVR rate to
24 weeks of IFN-a was only 6%, which increased to 13–19% with
48 weeks of treatment, largely due to a lower relapse rate [18,19].
Furthermore, genotyping of HCV showed that the SVR rate among
patients with genotype 1 was even less: 2% with 24 and 7–11%
with 48 weeks of treatment. Increasing the dose of IFN-a and
extending therapy for more than a year was minimally more
effective and considerably less well tolerated. Clearly what was
needed was another antiviral agent, to either replace or add to
IFN-a. The ﬁrst such agent was the oral nucleoside analogue
ribavirin.The ‘‘good old time’’ of interferon and ribavirin
The era of standard IFN-a and ribavirin
Another major step forward was made in the early 1990s when
Swedish authors had the idea to treat 10 patients with chronic
hepatitis C with ribavirin, an orally administered guanosine ana-
logue with a broad spectrum of antiviral action against both
DNA and RNA viral agents. A dose of 1000–1200 mg per dayJournal of Hepatology 201(500 or 600 mg twice per day) for 12 weeks was used. Serum
ALT levels signiﬁcantly decreased in all patients on treatment,
but increased back to baseline levels within 6 weeks
post-therapy [20]. In another study from the NIH [21], 13 patients
with chronic hepatitis C were treated for 6 months with a dose of
ribavirin that was increased at 2-month intervals from 600 mg to
1000 mg to 1200 mg daily. SerumALT levels decreased in all treat-
ed patients and normalized on treatment in 4 of them. Like in the
Swedish study, ALT levels gradually rose to near pretreatment
levels in all but one patient after cessation of ribavirin administra-
tion [21]. No reliable HCV RNA assaywas available at the time the-
se two studies were performed. It is only several years later that it
was shown that ribavirin only has a modest (less than 0.5 log HCV
RNA international units (IU)/ml on average) transient (a few days)
direct antiviral effect on HCV when given as a monotherapy [22].
The dramatic effect of ribavirin monotherapy on ALT levels led
Swedish and Italian groups to initiate two exploratory clinical tri-
als combining IFN-a and ribavirin in patients with chronic hep-
atitis C [23,24]. In the ﬁrst study, 20 non-responders to IFN-a
monotherapy were randomized to receive IFN-a alone or the
combination of IFN-a plus ribavirin for 24 weeks. None of the for-
mer, but 40% of the latter, achieved SVR [23]. In the other study, 9
of 10 patients who relapsed after and 3 of 10 patients who did not
respond to IFN-a monotherapy deﬁnitively cleared HCV RNA
after receiving 24 weeks of the combination of IFN-a and ribavir-
in [24].
Two large-scale multicenter, randomized, placebo-controlled
Phase III clinical trials provided evidence that the combination
of IFN-a2b (3 MU three times weekly) and ribavirin (1000 or
1200 mg daily according to body weight) is superior to IFN-a
monotherapy in treatment-naïve patients with chronic hepatitis
C. In the ﬁrst trial performed outside the US [19], SVR 24 weeks
after treatment (SVR24) was achieved in 43% of patients treated
for 48 weeks with the combination of IFN-a and ribavirin, 35%
of patients treated for 24 weeks with the combination of IFN-a
and ribavirin (p = 0.055 with the previous group), and only 19%
of patients treated for 48 weeks with IFN-a alone (p <0.001 with
both combination regimens). Logistic regression analysis identi-
ﬁed ﬁve independent factors signiﬁcantly associated with SVR:
HCV genotype 2 or 3, HCV RNA level <2 million copies/ml, age
40 years or less, minimal ﬁbrosis stage, and female sex [19].
In the second Phase III trial performed in the US [18], SVR was
achieved in 38% of patients treated for 48 weeks with the combi-
nation of IFN-a and ribavirin, 31% of patients treated for
24 weeks with the combination of IFN-a and ribavirin, 13% of
patients treated for 48 weeks with IFN-a alone and 6% of those
treated for 24 weeks with IFN-a alone (p <0.001 for the compar-
ison of IFN-a alone with both 24 or 48 weeks of combination
treatment). Among patients infected with HCV genotype 1, the
highest rates of SVR occurred in those treated for 48 weeks with
IFN-a and ribavirin, whereas in patients infected with HCV geno-
type 2 or 3, similar rates of SVR were achieved with 24 and
48 weeks of combination treatment [18].
The combination of standard IFN-a and ribavirin was
approved in 1999 as the standard-of-care treatment of chronic
hepatitis C. SVR was shown to be associated with favorable clin-
ical outcomes and improved health-related quality of life; in con-
trast, patients failing to achieve SVR progressed to more severe
liver disease [25].
Mathematical models of viral decay during IFN-a-based ther-
apy were useful to understand the steady-state kinetics of HCV5 vol. 62 j S87–S99 S89
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infection. The estimated half-life of free HCV virions in peripheral
blood was estimated to be about 2.7 h, with approximately 1012
virions produced and cleared each day [26]. After a short lag of a
few hours following the ﬁrst IFN-a injection, a biphasic decay of
viral replication was observed in patients receiving daily IFN-a
administration. The rapid ﬁrst phase viral decline was
dose-dependent and reﬂected blocking of HCV replication, as a
result of the direct antiviral action of IFN-a. The slower second
phase decline was hypothesized to result from the progressive
clearance of infected cells in the context of efﬁcient blocking of
HCV production [26]. Further studies showed that ribavirin addi-
tion does not alter the ﬁrst phase viral decline, but signiﬁcantly
accelerates the second phase decline through mechanisms that
remain elusive, explaining the higher cure rates in patients taking
both IFN-a and ribavirin [22,27]. Together, HCV kinetics studies
were helpful to emphasize the importance of sustained IFN-a
exposure and ribavirin in optimizing anti-HCV treatments
[28,29].
The era of pegylation
Standard IFN-a administration three times weekly was associated
with saw-toothed ups and downs of HCV RNA levels and a low like-
lihood of a steady second phase viral load decline [22]. Long-acting
IFNs, that could be administered once weekly while maintaining a
steady level of active drug, were generated by attaching the IFN-a
molecule to a polyethylene glycol moiety. Two pegylated-IFNs
(PegIFN) were developed: IFN-a2a was linked to a 40-kD branched
polyethylene glycol molecule, while IFN-a2b was linked to a 12-kD
linear polyethylene glycol molecule. Their elimination half-lives
were approximately 75 and 30 h, respectively.
PegIFN-a2a was given as a single weekly injection of
180 lg per week, while PegIFN-a2b dosing was weight-based
and, although various dosing strategies were evaluated, ultimate-
ly 1.5 lg/kg per week became the approved dose. PegIFN-a2a
and PegIFN-a2b both proved superior to their unpegylated coun-
terparts when given as monotherapy for 48 weeks [30,31]. As
with standard IFN, the addition of ribavirin to PegIFN-a improved
the rates of SVR. The Phase III trials demonstrated an important
effect of the HCV genotype. Indeed, the SVR rates were 42 to
46% in patients with genotype 1 infection compared to 76 to
82% in those infected with genotypes 2 or 3 [32,33]. Ultimately
a trial evaluating different durations and different ribavirin dos-
ing strategies clariﬁed that patients with genotype 1 infection
needed 48 weeks of therapy and a high, weight-based dose of
ribavirin, whereas those with genotypes 2 and 3 achieved high
rates of SVR (in the order of 80%) with only 24 weeks of therapy
and a ﬁxed dose (800 mg) of ribavirin [34].
Multivariate analyses identiﬁed independent predictors of
SVR with this regimen, including host factors (younger age, low
body mass index, mild-to-moderate ﬁbrosis, lack of steatosis
and insulin resistance, non-black ethnicity) and viral parameters
(HCV genotype other than 1 and 4, low baseline HCV RNA level).
The combination of PegIFN-a and ribavirin became the new
standard-of-care treatment of chronic hepatitis C and remained
so for about 10 years.
The era of response-guided therapy
The next step was the discovery, through post-hoc analysis of the
pivotal trials and performance of new studies, that treatmentS90 Journal of Hepatology 201duration should be modulated according to the on treatment
virologic responses. HCV RNA level measurement at baseline,
weeks 4, 12, and 24, at the end of treatment, and 24 weeks after
treatment withdrawal were used to characterize the virological
response: the rapid virologic response (RVR) was deﬁned as
undetectable HCV RNA at week 4 of therapy; the early virologic
response (EVR) as HCV RNA detectable at week 4 but unde-
tectable at week 12; the slow or delayed virologic response
(DVR) as HCV RNA detectable at week 12 but undetectable at
week 24 [35]. Patients with an RVR and a low baseline HCV
RNA level needed no more than 24 weeks of therapy [36];
patients who achieved an EVR required 48 weeks of therapy,
whereas patients with a DVR appeared to beneﬁt from extending
treatment to 72 weeks (but tolerability was a limiting factor)
[37–39]. Patients with less than a 2 log decline in HCV RNA level
at week 12 were unlikely to experience an SVR and could be
taken off therapy [35].
An important contribution to the ﬁeld was the discovery, by
means of genome-wide association studies (GWAS), of single
nucleotide polymorphisms located upstream of the
interleukin-28B (IL28B) gene strongly associated with the likeli-
hood of an SVR after PegIFN-a and ribavirin therapy [40]. Single
nucleotide polymorphism rs12979860 was the best baseline
SVR predictor in patients infected with genotype 1 receiving this
therapy [40]. The IL28B genotype is strongly associated with the
ethnic origin and a genetic marker of the patient’s IFN respon-
siveness [40]. More recently, another polymorphism in the same
region was identiﬁed, which affects the coding of a novel protein,
given the name IFN-k4, and both spontaneous HCV clearance and
the response to IFN-a-based therapy [41]. However, at the indi-
vidual level, better prediction is achieved by the monitoring of
viral kinetics on treatment.
The early era of direct-acting antiviral drugs
Major advances in the understanding of the molecular virology of
HCV came with the development of genotype 1 subgenomic and
genomic replicon systems and the identiﬁcation of the genotype
2a JFH1 clone, that leads to productive infection in cell culture
after transfection. With these new model systems and the resolu-
tion of the three-dimensional structure of key HCV enzymes, the
multiple steps of the HCV lifecycle were unraveled, identifying
multiple targets for drug discovery. Through a combination of
compound screening and rational drug design, small molecules
with potent activity against various HCV enzymes were discov-
ered. The recognition that the NS3-4A protease inhibitor cilupre-
vir (BILN-2061) could rapidly suppress HCV replication by 4 logs
in only 48 h validated this HCV enzyme as an optimal drug target.
Although concerns about toxicity limited the development of this
particular compound, it paved the way for the cascade of new
direct-acting antivirals (DAAs) that would follow. The two
ﬁrst-wave, ﬁrst-generation HCV NS3-4A protease inhibitors
telaprevir and boceprevir were approved in combination with
PegIFN-a and ribavirin for the treatment of chronic HCV geno-
type 1 infection in 2011 [42,43].
Telaprevir is an orally bioavailable NS3-4A protease inhibitor
that belongs to the a-ketoamide group and binds the HCV pro-
tease covalently. Boceprevir is an orally bioavailable pep-
tidomimetic a-ketoamide HCV NS3-4A protease inhibitor that
forms a covalent but reversible complex with the enzyme. Both
agents potently inhibit HCV replication, but they have a low5 vol. 62 j S87–S99
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barrier to resistance leading to the rapid selection of
resistance-associated variants when either used alone, or in com-
bination in a patient with a poor response to PegIFN-a.
In an attempt to circumvent this issue, the concept of the
‘‘lead-in‘‘ phase was introduced, in which patients were treated
with PegIFN-a and ribavirin for 4 weeks prior to introduction of
the protease inhibitor, with the hope to lower HCV RNA levels
prior to starting the DAA and thus reduce the incidence of treat-
ment failures and resistance. Although the lead-in did not reduce
rates of resistance or treatment failure in general, it was helpful
in determining which patients were likely to beneﬁt from pro-
tease inhibitor-based therapy. Indeed, patients with a less than
1 log IU/ml decline in HCV RNA during the 4-week lead-in had
a low chance of response, particularly if they had previously
failed therapy and had advanced ﬁbrosis [44–46].
The lead-in was a measure of IFN responsiveness, the key
determinant to the outcome of treatment with ﬁrst-generation
protease inhibitors. The importance of the IFN-response was par-
ticularly evident in patients who had failed prior PegIFN-a and
ribavirin therapy. Those who had responded and relapsed, prov-
ing their intrinsic responsiveness to IFN, achieved high rates of
SVR (>80%), even if they had cirrhosis. In contrast, patients with
a prior null response to dual therapy had a low chance of
responding to triple therapy (in the order of 30%) despite a full
48 weeks of treatment [44–46]. Other factors associated with
the IFN-response (IL28B genotype, ethnicity, ﬁbrosis stage, etc.)
were also predictive of response to triple therapy with
PegIFN-a, ribavirin and either protease inhibitor [44–50].
Patients with multiple negative predictors such as a prior null
response and cirrhosis had a very low chance of SVR, in the order
of 15%.
Due to different Phase III clinical trial designs, telaprevir and
boceprevir were used differently in combination with PegIFN-a
and ribavirin. Boceprevir was approved with a 4-week lead-in
with PegIFN-a and ribavirin alone, continued for up to 44 weeks
of dosing, whereas telaprevir was given to all patients for the ini-
tial 12 weeks of treatment with PegIFN-a and ribavirin, followed
by 12 to 36 weeks of PegIFN-a and ribavirin alone. Differing regi-
mens, response deﬁnitions, response-guided therapy approaches
and futility rules between the two protease inhibitors signiﬁcant-
ly complicated treatment. The drugs were also both associated
with additional side effects to those already present with
PegIFN-a and RBV. Both telaprevir and boceprevir caused sig-
niﬁcant anemia, and telaprevir was also associated with cuta-
neous reactions, which on rare occasion were severe
(Stevens-Johnson syndrome, drug rash with eosinophilia and sys-
temic symptoms [DRESS] syndrome) or even fatal [44–48].
Despite the challenges with these new therapies, the improve-
ments in SVR over PegIFN-a and ribavirin alone reported in the
clinical trials led to rapid and enthusiastic treatment uptake with
these new agents.
Treatment in the real world setting told a different story than
the highly selected clinical trials. The CUPIC trial evaluated
patients with cirrhosis who received treatment with either
ﬁrst-wave, ﬁrst-generation protease inhibitors through the
French Early Access Program [49,50]. Adverse events, including
serious and even fatal events, were reported with much higher
frequency than in the Phase III trials. Serious adverse events were
particularly common in patients with cirrhosis who had early
signs of portal hypertension (thrombocytopenia) and liver syn-
thetic dysfunction (hypoalbuminemia). Patients with a plateletJournal of Hepatology 201count below 100,000/ll and a serum albumin level less than
35 g/L had a 41% chance of experiencing a serious adverse event
during therapy. In addition to the unexpected toxicity, SVR rates
were lower than reported in controlled trials [49,50]. Although
side effect management improved with experience, other real
world registries also reported greater toxicity and lower efﬁcacy
for both agents. There was clearly room for improvement.The DAA revolution
The development of HCV DAAs has occurred extremely rapidly,
moving from approval of ﬁrst-wave, ﬁrst-generation protease
inhibitors that were combined with PegIFN-a and ribavirin to
all-oral single tablet DAA combinations, in less than 4 years.
Despite the dramatic success of DAA development, there were
challenges along the way. Initial treatment regimens were com-
plicated and proved less effective and more toxic in the real
world than in clinical trials. Multiple promising agents were
abandoned for toxicity, including fatal complications in a small
number of patients. Ultimately, combinations of agents targeting
different stages of the lifecycle proved highly effective.
HCV DAAs approved and in development
The HCV lifecycle can be blocked at many steps [51,52]. HCV
DAAs on the market or in clinical development include NS3-4A
protease inhibitors, nucleotide analogue inhibitors of the HCV
RNA-dependent RNA polymerase (RdRp), non-nucleoside inhibi-
tors of the HCV RdRp and inhibitors of the non-structural 5A
(NS5A) protein (Table 1). These drugs differ in their activity
against the different HCV genotypes and their barrier to
resistance.
NS3-4A protease inhibitors bind the catalytic site of the
enzyme and block post-translational processing of the viral
polyprotein. The ﬁrst-wave, ﬁrst-generation NS3-4A protease
inhibitors, telaprevir and boceprevir, were active essentially
against genotype 1, had low barriers to resistance and, as dis-
cussed above, were poorly tolerated. The second-wave,
ﬁrst-generation NS3-4A protease inhibitors are active against
genotypes 1, 2, and 4, but not against genotype 3. They have a
low barrier to resistance. Some of them can be boosted by riton-
avir to extend dosing intervals while increasing patient exposure.
Second-generation NS3-4A protease inhibitors have pangenotyp-
ic antiviral activity and a higher barrier to resistance than
ﬁrst-generation drugs.
Nucleotide analogues act as false substrates for the HCV RdRp,
leading to chain termination after being incorporated into the
newly synthesized viral RNA. They need two intracellular phos-
phorylations to become active at the target site. Nucleotide ana-
logues are active against all HCV genotypes and have a high
barrier to resistance.
Non-nucleoside inhibitors of HCV RdRp bind to one of 4
allosteric sites of the enzyme and alter the conformation of
the RdRp, thereby blocking its catalytic function. Current
non-nucleoside HCV RdRp inhibitors are generally active against
HCV genotype 1 and have a low barrier to resistance.
NS5A inhibitors bind to domain 1 of the NS5A protein and
block its ability to regulate HCV replication within the replication
complex [53]. In addition, NS5A inhibitors inhibit assembly and
release of viral particles [54,55]. Some ﬁrst-generation NS5A5 vol. 62 j S87–S99 S91
Table 1. Approved DAAs and DAAs in clinical development at the beginning of 2015.
Agent class Generation Compound Phase of clinical development
NS3-4A protease inhibitors First-wave, first-generation Telaprevir
Boceprevir
Approved
Second-wave, first-generation Simeprevir
Paritaprevir/r
Approved
Asunaprevir
Vaniprevir
Vedroprevir
Sovaprevir
In clinical development
Second-generation Grazoprevir
ACH-2684
In clinical development
Nucleoside/nucleotide analogues Nucleotide analogues Sofosbuvir Approved
MK-3682
ACH-3422
AL-335
In clinical development
Non-nucleoside inhibitors of the HCV 
RNA-dependent RNA polymerase
Palm domain I inhibitors Dasabuvir Approved
Thumb domain I inhibitors Beclabuvir In clinical development
Thumb domain II inhibitors GS-9669 In clinical development
NS5A inhibitors First-generation Daclatasvir
Ledipasvir
Ombitasvir
Approved
Second-generation Elbasvir
GS-5816
ACH-3102
In clinical development
/r, ritonavir-boosted.
Reviewinhibitors have pangenotypic activity whereas others are poorly
active against genotype 3. They have a low barrier to resistance.
Second-generation NS5A inhibitors are active against all HCV
genotypes, but their barrier to resistance appears to be only mod-
estly improved compared to ﬁrst-generation compounds [56].
The end of the IFN era
In 2014, several strategies based on the use of a triple combina-
tion of PegIFN-a, ribavirin and one DAA were approved. Among
them, the most attractive was the combination of PegIFN-a, rib-
avirin and the nucleotide analogue sofosbuvir (400 mg once dai-
ly), that yielded high SVR rates in patients infected with all
genotypes after only 12 weeks of therapy. In the NEUTRINO
Phase III trial [57], the SVR rates were 89% in genotype 1 (92%
in subtype 1a, 82% in subtype 1b) and 96% in genotype 4 patients.
One patient with genotype 5, and six patients with genotype 6
also achieved an SVR. The overall SVR rates were 92% in patients
without cirrhosis vs. 80% in those with cirrhosis. Adverse events
were similar to those reported with PegIFN-a and ribavirin alone.
Importantly, treatment failures were not associated with the
selection of resistant HCV variants [57]. Another Phase II study
in treatment-experienced patients showed SVR rates of 96% and
83% with this regimen in patients with genotype 2 or 3 infection,
respectively [58].
The triple combination of PegIFN-a, ribavirin and the
second-wave, ﬁrst-generation NS3-4A protease inhibitor
simeprevir (150 mg once daily) has also been approved in 2014
for patients infected with HCV genotype 1 (and 4 in Europe),
based on the results of the Phase III QUEST-1 and QUEST-2 stud-
ies in treatment-naïve HCV genotype 1 patients [59,60]. In these
trials, the SVR rates were 80% and 81% vs. 50% and 50% in the con-
trol groups, respectively. They were 75% and 85% in patientsS92 Journal of Hepatology 201infected with subtypes 1a and 1b, respectively. This difference
was due to a 58% SVR rate in the subgroup of patients infected
with subtype 1a who had a detectable Q80K substitution in the
NS3 protease sequence at baseline vs. 84% in those without
detectable Q80K [59,60]. Because this ﬁnding implied that
patients should be tested prior to therapy for HCV subtype and,
in those infected with subtype 1a, for the presence of the Q80K
substitution [61], this combination has virtually not been used.
Instead, the presence of both sofosbuvir and simeprevir on the
market allowed practitioners to use them together, IFN-free,
either off-label (US) or within the framework of early access pro-
grams (Europe). Simeprevir was well tolerated in all Phase III
studies, although pruritus and rashes were slightly more frequent
than in the control arms. Approximately 10% of patients devel-
oped mild, transient hyperbilirubinemia without changes in
other liver parameters [61]. At the time of treatment failure,
patients who did not respond to simeprevir-containing therapies
harbored HCV protease inhibitor-resistant variants that disap-
peared as dominant species within 16 months post-treatment
[62].
Phase II data were reported with the combination of PegIFN-a,
ribavirin and the ﬁrst-generation NS5A inhibitor daclatasvir
(approved in the European Union only) [63,64], but this combina-
tion has not been used. Instead, the IFN-free combination of
sofosbuvir and daclatasvir has been widely used in Europe, thus
far essentially within the framework of early access programs
in patients with advanced liver disease.
The dawn of the IFN-free era
Small Phase II studies with sofosbuvir and ribavirin in genotypes
2 and 3, and with a protease inhibitor (asunaprevir) and an NS5A
inhibitor (daclatasvir) in genotype 1, proved that SVR was5 vol. 62 j S87–S99
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possible without the need for PegIFN-a. In the FISSION Phase III
trial in treatment-naïve patients [57], sofosbuvir and ribavirin
given for 12 weeks yielded SVR rates of 95% in genotype 2 and
56% in genotype 3 patients vs. 78% and 63% with PegIFN-a and
ribavirin for 24 weeks. In the Phase III FUSION trial in
treatment-experienced patients treated with sofosbuvir plus rib-
avirin for 12 or 16 weeks [65], the SVR rates were 82% and 89% in
genotype 2, and 30% and 62% in genotype 3 patients, respectively.
In the VALENCE Phase III trial, in genotype 2-infected patients
treated for 12 weeks, the SVR rates were 97% in naïve
non-cirrhotic patients, 100% in naïve cirrhotic patients, 91% in
experienced non-cirrhotic patients, and 88% in experienced
cirrhotic patients. In genotype 3-infected patients treated
for 24 weeks, they were 94%, 92%, 87%, and 60%, respectively
[66]. The combination of sofosbuvir and ribavirin was well
tolerated and relapses were not related to the selection of
sofosbuvir-resistant HCV variants [57,65,66]. The
standard-of-care treatment in patients infected with HCV geno-
type 2 is now the combination of sofosbuvir and ribavirin for
12 weeks. Treatment-experienced cirrhotic patients may need
16 to 20 weeks of therapy [61]. In patients infected with geno-
type 2, preliminary ‘‘real-life’’ data showed SVR rates in keeping
with the results of Phase III trials [67]. Patients infected with
genotype 3 must be treated for 24 weeks with the combination
of sofosbuvir plus ribavirin or for 12 weeks with sofosbuvir,
PegIFN-a and ribavirin.
The IFN-free combination of sofosbuvir (400 mg daily) plus
simeprevir (150 mg daily) was used based on the results of the
small-size Phase II COSMOS study in patients infected with geno-
type 1 [68]. In the ﬁrst cohort of prior null responders with F0–F2
METAVIR scores, the SVR rates were 96% and 93% after 12 weeks,
and 79% and 93% after 24 weeks, with or without ribavirin,
respectively. In the second cohort of treatment-naïve and –expe-
rienced patients with F3–F4 METAVIR scores, the SVR rates were
93% and 93% after 12 weeks, and 93% and 100% after 24 weeks,
with or without ribavirin, respectively. When patients from both
cohorts were pooled, the SVR rates in patients infected with
subtype 1a with a detectable Q80K substitution at baseline were
88% and 89% after 12 weeks, and 83% and 100% after 24 weeks,
with or without ribavirin, respectively. The combination was well
tolerated [68]. Recent preliminary real-life data from the US
showed SVR rates slightly below those in the COSMOS trial in
patients with genotype 1 infection: 82% SVR12 in the TRIO study,
89% SVR4 in the TARGET study [67,69].
The combination of sofosbuvir (400 mg daily) and daclatasvir
(60 mg daily) has been widely used in patients with advanced liv-
er disease in Europe, based on the results of a Phase II study in
patients infected with genotype 1 reporting SVR rates between
95% and 100% after 12 or 24 weeks with or without ribavirin in
treatment-naïve patients and in patients who did not respond
to the combination of PegIFN-a, ribavirin, and either telaprevir
or boceprevir [70]. The combination was well tolerated over the
course of therapy. Real-life data are awaited. This combination
currently is the best IFN-free option for patients infected with
genotype 3.
The triumph of IFN-free regimens
Two new IFN-free, DAA-based combinations have been approved
in late 2014/early 2015 in the US and Europe. The combination of
sofosbuvir (400 mg) plus ledipasvir (90 mg) in one single pillJournal of Hepatology 201administered daily, with or without ribavirin according to the
severity of liver disease, is approved for genotype 1 in the US,
for genotypes 1, 3, and 4 in the European Union (indication in
genotype 3 patients debatable based on available data). The triple
combination of ritonavir-boosted paritaprevir and ombitasvir in
one single pill (50 mg/75 mg/12.5 mg per pill, 2 pills per day)
plus dasabuvir in another pill (250 mg per pill, 2 pills per day),
with or without ribavirin according to the HCV subtype and the
presence of cirrhosis, is approved for HCV genotype 1.
Three Phase III studies have been performed with the
sofosbuvir-ledipasvir combination in patients infected with
genotype 1. In ION-1 in treatment-naïve patients, the SVR rates
were 99% and 97% after 12 weeks, 98% and 99% after 24 weeks,
with or without ribavirin, respectively [71]. In ION-3, also in
treatment-naïve non-cirrhotic patients, the SVR rates were 94%
for 8 weeks without ribavirin, 93% for 8 weeks with ribavirin and
95% for 12 weekswithout ribavirin [72]. Post-hoc analysis suggest-
ed that 8 weeks of treatment is sufﬁcient in treatment-naïve
patients with an HCV RNA level <6 million (6.7 log) IU/ml at base-
line (to be conﬁrmed in the real-life setting). In ION-2 in
treatment-experienced patients, the SVR rates were 94% and 96%
after 12 weeks, 99% and 99% after 24 weeks, with or without rib-
avirin, respectively [73]. No major safety signal was reported.
Recent data suggest that the additionof ribavirin allowsone to lim-
it treatment duration to 12 weeks, even in patients with advanced
liver disease, including patientswith compensated cirrhosis (espe-
cially if they are treatment-experienced), patientswithdecompen-
sated cirrhosis and subjects in the pre- and post-liver transplant
setting [74–77]. High SVR rates can be achieved in these patients,
in the order of 85 to 95% according to the severity of liver disease.
High SVR rates have also been reported with the combination of
sofosbuvir and ledipasvir in genotype 4 and 6 patients [78,79].
Patients who fail to eradicate HCV on sofosbuvir plus ledipasvir
are likely to select viral populations that are resistant to the
NS5A inhibitor but not to sofosbuvir. The NS5A resistant viruses
may persist for many months to years as dominant viral popula-
tions, and their impact on subsequent retreatment is unknown.
The approval of the triple combination of ritonavir-boosted
paritaprevir, ombitasvir and dasabuvir in patients infected with
genotype 1 was supported by six Phase III clinical trials. In
SAPPHIRE-I in treatment-naïve patients without cirrhosis treated
for 12 weeks, the SVR rates with ribavirin were 95% in subtype 1a
and 98% in subtype 1b [80]. In PEARL-IV, the SVR rates were 97%
and 90% with and without ribavirin, respectively, in patients
infected with subtype 1a, suggesting that ribavirin is needed with
this subtype [81]. In PEARL-III, the SVR rates were 99% and 99%
with and without ribavirin, respectively, in patients infected with
subtype 1b, suggesting that ribavirin is not needed with this sub-
type [81]. In non-cirrhotic treatment-experienced patients treat-
ed for 12 weeks with ribavirin in SAPPHIRE-II, the SVR rates were
96% in subtype 1a and 97% in subtype 1b [82]. SVR was achieved
in 97% with ribavirin and 100% without ribavirin in patients
infected with subtype 1b in PEARL-II, conﬁrming that ribavirin
is not needed with this subtype [83]. In treatment-naïve and –
experienced patients with HCV genotype 1 infection and com-
pensated cirrhosis, the rates of SVR were 92% after 12 weeks
and 96% after 24 weeks of the triple DAA combination plus rib-
avirin. The one group of patients who beneﬁted from 24 weeks
of treatment was the cohort of treatment-experienced cirrhotic
patients with subtype 1a infection [82]. The triple combination
of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir has5 vol. 62 j S87–S99 S93
Table 2. Requirements for HCV elimination in high-income countries.
Diagnostics Treatment regimens Health infrastructure Policy
• Inexpensive, point-of-
care documentation of 
viremia
• Widespread availability 
of non-invasive fibrosis 
staging
• One-size-fits-all regimens 
(all genotypes, all disease 
stages)
• 95% SVR all sub-populations
• Few adverse events
• Few/no drug interactions
• HCV vaccine*
• Treatment delivery in primary 
care facilities
• Immediate link to treatment at 
time of diagnosis
• High treatment in marginalized 
populations
• Harm reduction strategies
• Elimination of iatrogenic spread*
• National action plan for 
HCV elimination
• Drug pricing reform
⁄Priority requirement in low/middle income countries.
Reviewbeen shown to be equally effective in HIV-coinfected patients and
those after liver transplantation. However, drug-drug interactions
are an important consideration, related in particular to ritonavir
and paritaprevir [84,85]. High SVR rates were also reported in
patients infected with genotype 4 with the combination of
ritonavir-boosted paritaprevir and ombitasvir (without dasabu-
vir) [86]. This drug combination was well tolerated. Patients
who fail to eradicate HCV on these combinations are likely to
select viral populations that are resistant to one, two, or three
of the DAAs administered.
Other treatment regimens are at the clinical developmental
stage and could reach the market within the next couple of years.
They include nucleotide analogue-based regimens;
nucleotide-free triple combinations of three drugs, each with a
low barrier to resistance, which collectively achieve a high barrier
to resistance; and nucleotide-free double combinations of drugs
that include at least one ‘‘second-generation’’ drug with a higher
barrier to resistance [52].
What comes next?
The unprecedented progress in HCV therapeutics has created a
situation in which it is likely that virtually all infected individuals
will be able to be cured with well tolerated oral regimens if they
are able to access therapy. Thus, the challenges in the HCV ﬁeld
are moving rapidly from drug discovery to treatment access
and delivery. If these challenges can be addressed, the new HCV
therapies present the rare possibility in medicine of local disease
elimination and, potentially, even global disease eradication. To
achieve these lofty goals, much more than effective, well tolerat-
ed therapies will be required. The issues will vary greatly depend-
ing on the local epidemiology, burden of disease, healthcare
infrastructure and the local ﬁnancial situation.
Is elimination possible?
The terms ‘‘elimination’’ and ‘‘eradication’’ are often used inter-
changeably despite having different meanings. Elimination refers
to ridding a deﬁned region or population, such as a state or coun-
try, of HCV [87]. Eradication means obliterating HCV from the
earth, as has been done only with smallpox and rinderpest thus
far [87]. Although the lack of an animal reservoir means that
HCV could theoretically be eradicated globally [88], it is extreme-
ly unlikely that true eradication is feasible and almost certainly
not without an efﬁcient prophylactic vaccine. In contrast,
elimination through treatment may be possible, although it will
be challenging, at least in wealthy areas [89]. However, elimina-
tion will require much more than 100% SVR rates (Table 2):S94 Journal of Hepatology 201beyond issues remaining with the drug regimens themselves,
major changes will be required in access to care, delivery of care
and drug pricing policies. Without strong advocacy and political
activism, these changes are unlikely to occur.
The regimens
The ﬁrst challenge will be to reﬁne the current regimens, to not
only maximize rates of SVR but to simplify therapy. Indeed,
elimination through treatment will require that all infected indi-
viduals receive therapy, which can only be accomplished if treat-
ment is done in primary care settings. Compared to difﬁcult,
long-duration, IFN-based therapies, single tablet regimens are
remarkably effective and relatively easy to use. However, treat-
ment still requires specialty care, greatly limiting the prospect
of widespread implementation. The subtleties of differing regi-
mens with differing durations for speciﬁc sub-populations,
whether deﬁned by genotype, subtype, presence of cirrhosis or
co-morbidities, will discourage new treaters from entering the
ﬁeld. Although some of the combinations in development hold
promise for very simpliﬁed regimens that will be effective in
almost all populations, some reﬁnement is still required.
Currently, the priority is to maximize SVR while minimizing
duration of therapy. Emerging data suggest that extending treat-
ment duration overcomes reduced efﬁcacy even in the hardest to
cure sub-populations [71,73,82,90]. Although there are still some
populations, such as treatment-experienced patients with geno-
type 3 infection and advanced cirrhosis for whom better thera-
pies are still required, it is likely that there will be regimens
that truly cure everyone provided they are treated ‘‘long enough’’.
However, the long enough is a major issue. Given current drug
pricing, there is a major incentive to minimize the duration of
therapy and hence the cost of treatment. Nevertheless, with
extremely safe and well tolerated regimens, there is little harm
in overtreatment aside from cost.
A one-size-ﬁts-all paradigm will be required if treatment is to
move to primary care. The goal would be to test for viremia (or a
simpler and cheaper measure of active infection such as HCV core
antigen) and then institute treatment for a ﬁxed duration,
irrespective of genotype, subtype and, ideally, stage of liver dis-
ease. To ensure everyone achieves SVR with this approach, some
(perhaps most) individuals will receive longer therapy than they
might have required, which is what was done with IFN-based
regimens. For this approach to gain acceptance, drug pricing
reform is necessary. Although in the currentmodel it may bemore
cost-effective to shorten duration and then retreat relapsers, it
would be preferable if the cost of therapy did not differ by
duration and everyone was cured with one ﬁxed duration course.5 vol. 62 j S87–S99
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Access to care: knowledge is key
The ﬁrst and perhaps largest hurdle to accessing treatment cur-
rently is under-diagnosis. Although some countries, such as
France, Scotland and Australia, have done a good job of identify-
ing those infected, most countries have diagnosis rates well
below 50% [91]. In many countries, the diagnosis rate is either
completely unknown or estimates are based on poor quality data
[92]. This is a critical issue: on the one hand undiagnosed indi-
viduals do not seek treatment, but more importantly, without a
good handle on the prevalence and burden of HCV, governments
cannot accurately budget for the resources required to scale up
treatment. The World Health Organization found that only 47
countries had national strategies addressing viral hepatitis and,
on further inspection, only 18 had viral hepatitis-speciﬁc action
plans [93].
With the current alarm over drug pricing, governments may
be reluctant to improve diagnosis rates for fear that they will
then be responsible for treating those they identify. This short-
sighted strategy will result in dealing with the consequences of
end-stage liver disease in the future, but sadly may be rational-
ized by governments who recognize that it will not be their
responsibility. Political activism has been extremely effective in
other areas, particularly HIV, and will need to improve in the
HCV community in order for governments to start taking action.
Once the local epidemiology has been clariﬁed, the most
appropriate strategies for case-ﬁnding can be developed. For
example, in the US, birth cohort screening was shown to be
cost-effective and has been adopted, while other strategies are
likely more effective in Europe and other regions [94]. Even the
speciﬁcs of a policy may differ by country. In Canada, the epi-
demiology supports extending birth cohort screening to include
those born between 1945 and 1975 rather than 1945 and 1965
in the US [95]. In almost all regions, some type of
population-based screening will be required to identify the
majority of infected individuals.
Initial anti-HCV testing should be linked immediately to tests
for viremia, whether HCV RNA or a cheaper/more accessible
approach such as HCV core antigen. Drug development has out-
paced improvement in diagnostics, which is an important issue
particularly in resource-limited regions where HCV RNA testing
might actually surpass the cost of HCV treatment [96].
Development of rapid, ideally point-of-care, diagnostics for HCV
viremia is needed [96].
Diagnosis is only the ﬁrst step. Data from the US on the cas-
cade of care have shown that there is an immediate drop from
initial diagnosis to any type of follow-up [97,98]. Individuals
are indeed much more likely to follow-up in the clinic in which
they were diagnosed, usually a primary care facility, than to
attend a specialty clinic [99]. Ideally, individuals would ﬁnd out
the result of testing at the time it is performed and would be
immediately linked to a discussion of treatment initiation. For
this to occur, treatment must move out of specialty clinics.
Delivery of care
The complexity of therapy has required and arguably still
requires specialty care for safe and effective delivery. The
removal of IFN greatly simpliﬁes treatment and makes many
more patients eligible for therapy, but further reﬁnements will
be required for effective delivery in a primary care settingJournal of Hepatology 201without additional support. Adoption of HIV treatment in prima-
ry care has shown that treatment can be delivered by
non-specialists. However, in most cases, primary care providers
who treat HIV have developed a sustained interest and expertise
in this area [100]. The same model could be applied in HCV, ide-
ally among primary care providers with a high prevalence of HCV
in their patient populations, such as methadone and addiction
clinics. To gain the initial expertise to start treating HCV, models
of peer support such as Project ECHO, may be very useful. Project
ECHO uses videoconferencing technology to connect specialists
to primary care providers, allowing for co-management of
patients as well as training. Initially pioneered in New Mexico
with evidence showing equivalent outcomes in patients treated
in a tertiary care facility or in primary care [101], Project ECHO
has been replicated in many regions and is an ideal model for
management of HCV and many chronic diseases [102].
Beyond treatment
To truly achieve elimination, more than treatment will be
required. Widespread treatment may eventually eliminate preva-
lent cases. However, to eliminate HCV, incidence must also be
addressed. Globally, iatrogenic spread remains the most common
route of infection. However, in high- and many middle-income
countries, injection drug use is the driver of transmission [91].
High uptake of antiretroviral therapy has been shown to reduce
HIV transmission, making treatment as prevention a major strat-
egy of global HIV control [103]. ‘‘Cure as prevention’’ has the
potential to be even more effective for HCV. Even modest treat-
ment uptake among people who inject drugs has the potential
to signiﬁcantly curb incident infections and to ultimately
decrease population prevalence [104]. There are many challenges
of delivering care in marginalized populations; however, numer-
ous pilot projects have shown that it is feasible [105]. Treatment
should be combined with harm reduction strategies such as opi-
oid substitution therapy and needle syringe programs, which
have beneﬁts beyond HCV [105].
Addressing iatrogenic spread and contemplating elimination
in low and middle-income countries is a more daunting task.
Arguably iatrogenic transmission is largely a ﬁnancial issue due
to the lack of resources for reliable sterilized equipment.
However, in many countries, injection therapy is seen as ‘‘prefer-
able’’ by patients for many medical conditions, and delivery of
care, including injections, is often given by relatively untrained
practitioners [106]. Intra-familial spread has also been
documented in high prevalence regions such as Egypt [107].
Even if treatment is made widely available, it is unlikely to curb
incidence and reduce prevalence signiﬁcantly without other
strategies. Hopefully the progress in treatment will not deter
government and industry from supporting research in effective
prophylactic vaccine development.
Drug prices
The release of sofosbuvir at a price of $1000 USD per pill in the US
led to uproar in the lay press. Although arguments have been
made to justify the cost relative to other therapies in terms of
cost-per-cure, cost-effectiveness or other measures, the fact
remains that the price of therapies will be a major impediment
to their widespread use. Even if these therapies are
cost-effective, at their current prices, they are not cost-saving,5 vol. 62 j S87–S99 S95
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meaning that even when taking into account the downstream
savings of reduced complications of HCV, treatment costs more
than not treating [108]. Furthermore, the high prevalence of
HCV means that the budget impact will be enormous for payers
if everyone is treated immediately.
The most common strategy to address the cost is to limit
access to therapy, usually based on the severity of liver disease.
Although a rational approach, this will markedly delay progress
towards elimination and is difﬁcult for infected individuals to
accept. The idea that ‘‘one is not sick enough’’ to warrant treat-
ment is hard to rationalize. In addition, unless treatment is limit-
ed to those with cirrhosis, accurate ﬁbrosis staging is required,
which is often not available, particularly in primary care. The
simplest answer to the price question is to simply lower the costs
of the drugs.
Approaches such as pricing per treatment course rather than
per pill would justify slightly longer courses of therapy to avoid
relapse and to allow for one-size-ﬁts-all treatment paradigms.
In addition, novel payment approaches such as amortizing the
cost of therapy over many years would make it more affordable
for payers. Although the decision to cut prices in lower income
regions is laudable, the reality is that in middle- and
high-income countries, without major reform, drug pricing will
be a major impediment to treatment and ultimately will be the
downfall of elimination and eradication strategies.Conclusions
Jay Hoofnagle
‘‘The progress in therapy of hepatitis C since its humble begin-
nings 30 years ago has exceeded all expectations and is truly
remarkable and welcomed; these feelings are soured only by
the excessive prices being demanded for these life-saving
therapies.’’
Stefan Zeuzem
‘‘The treatment with IFN and ribavirin is history. However, it will
remain a ﬁne textbook example how intensive clinical research
can enhance outcome (here: sustained virological response) with
modiﬁcation of dose and treatment duration of available drugs
and likewise improve tolerability and safety of these drugs by
adequate side effect management.’’
Jordan Feld
‘‘I feel a bit like a surfer who after ﬁguring out how to just stand
up on the board suddenly catches a tsunami and takes the ride of
a lifetime. I entered the HCV ﬁeld at just the right time. As I ﬁn-
ished my training, PegIFN-awas introduced. At the time, this was
a major step forward as we ﬁnally started seeing a reasonable
number of cures. But it was also a great research opportunity.
Understanding why half the population did not respond to treat-
ment became my primary goal. Although that was our focus,
studying IFN responses (or the lack thereof) had the added
beneﬁt of improving our understanding of the innate antiviral
immune response. It is because of HCV that many of the pathogen
recognition and innate immune signaling pathways have
been clariﬁed. It has therefore been bittersweet to see theS96 Journal of Hepatology 201unprecedented progress in HCV therapy. That we would be cur-
ing near 100% of patients in the near future with easy to take
tablets was beyond contemplation just a few years ago. This is
an amazing advance and the scientists involved in the virology
and drug discovery should be congratulated. I hope however that
we remember that HCV has taught us a great deal and many of
the questions that are no longer clinically important may still
be very relevant to science.
Being part of the beginning of the end of HCV has been an
exciting ride. The lightening speed with which the ﬁeld has
moved has been exhilarating and I feel lucky to have been in
the right place at the right time. The good news is that I am young
enough that I will hopefully see the real fruits of all of this labor. I
look forward to the day when I tell residents in disbelief that
HCV, that simple disease that we cure with a few weeks of pills,
was the commonest indication for liver transplantation and the
infectious disease that led to the greatest number of lives lost
in Canada. I am not sure that I will see a world without HCV
but I am optimistic that I will live in and visit many countries free
of HCV. Making that a reality will be no small task; but it will be
well worth the effort.’’
Jean-Michel Pawlotsky
‘‘Three generations of scientists/hepatologists who witnessed the
miracle of hepatitis C, from discovery to cure, joined their forces
and memories to write this article. It has been an incredible luck
and honor to be part of the HCV story, with them. This is not the
end of the tunnel, but we see the light. Although I am not as
young as Jordan Feld, I still hope I will also see the real fruits of
all of this labor. . ..’’Conﬂict of interest disclosure
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